Analyst Price Forecast Suggests 110.68% Upside
As of August 31, 2023, the average one-year price target for Geron is 4.93. The forecasts range from a low of 4.04 to a high of $6.30. The average price target represents an increase of 110.68% from its latest reported closing price of 2.34.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Geron is 2MM, an increase of 402.00%. The projected annual non-GAAP EPS is -0.44.
What is the Fund Sentiment?
There are 345 funds or institutions reporting positions in Geron. This is an increase of 21 owner(s) or 6.48% in the last quarter. Average portfolio weight of all funds dedicated to GERN is 0.19%, an increase of 56.20%. Total shares owned by institutions increased in the last three months by 6.23% to 356,951K shares. The put/call ratio of GERN is 0.36, indicating a bullish outlook.
What are Other Shareholders Doing?
Ra Capital Management holds 31,545K shares representing 6.03% ownership of the company. No change in the last quarter.
Deep Track Capital holds 24,171K shares representing 4.62% ownership of the company. In it’s prior filing, the firm reported owning 26,867K shares, representing a decrease of 11.16%. The firm increased its portfolio allocation in GERN by 49.99% over the last quarter.
TCG Crossover Management holds 23,590K shares representing 4.51% ownership of the company. In it’s prior filing, the firm reported owning 17,765K shares, representing an increase of 24.69%. The firm increased its portfolio allocation in GERN by 65.26% over the last quarter.
NEA Management Company holds 21,348K shares representing 4.08% ownership of the company. No change in the last quarter.
Vivo Capital holds 16,525K shares representing 3.16% ownership of the company. In it’s prior filing, the firm reported owning 19,283K shares, representing a decrease of 16.69%. The firm increased its portfolio allocation in GERN by 26.10% over the last quarter.
Geron Background Information
(This description is provided by the company.)
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.
This article originally appeared on Fintel
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.